Clinical Trials Browser

Phase 2/3 × Carcinoma, Medullary × anlotinib × Clear all

NCT02586350 2019-05-21

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Phase 2/3 Completed

Carcinoma, Medullary